Our board comprise member with both industry specific experience and business understanding, and have all a long track record of current and previous executive- and board positions.
Board of directors
Anders Tuv
Chair of the New Board of Directors, co-founder
About Close
Anders Tuv is the Managing Director of Radforsk Invest, a life science investment company with a focus on cutting edge immunotherapies and precision medicines. A seasoned entrepreneur and investment expert in the life sciences, Anders has driven strategic growth and value through operations, management, business development, global licensing, M&A, IPOs, trade sales and research collaborations. Anders is a co-founder of Zelluna and was the company`s first Chairperson. His leadership extends to previously chairing the boards of Nykode Therapeutics and Oncoimmunity and currently serving on the boards of Nextera AS, OnDosis AB, ClexBio/Nordovo Biosciences AS, DoMore Diagnostics and Aleap Ventues.
Bent Jakobsen
Board member
About Close
Mr. Jakobsen is a pioneer of T cell receptor therapy for cancer with over two decades’ experience of establishing and providing scientific direction to leading T cell receptor companies such as Adaptimmune Therapeutics and Immunocore (both now listed on NASDAQ). In his academic career, Bent was Head of the Immune Receptor Group at the Oxford Institute of Molecular Medicine (1993 to 2000) and prior to this worked for the Danish Natural Research Council and at the Laboratory of Molecular Biology of the Medical Research Council in Cambridge.
Bent is a visiting professor at the University of Oxford, has authored numerous scientific papers and is considered a world expert in the field of T cell receptor immunology. In 2015, he was recognised for his contribution to medical science with an election to the Fellowship of the Academy of Medical Sciences.
Eva-Lotta Allan
Board memeber
About Close
Eva-Lotta has >30 years of cooperate, business development and operational experience from the biotechnology industry. During her five years as Immunocores CBO she raised $320 million in a series A round and established significant partnerships with top pharmaceutical companies. She was previously at Ablynx, as CBO for seven years participating in taking the company public and completed several strategic partnerships. Before that she was Senior Director Business Development and Site Operations (Europe) at Vertex Pharmaceuticals. Eva-Lotta is currently Non-Executive Chair of Draupnir Bio and Maxion Therapeutics and Non-Executive Director of Almirall (and Chair of the Nomination and Remuneration Committee) and Crescendo Biologics. Previous board appointments include BIA, Aleta Biotherapeutics, Targovax, C4X Discovery, Immunocore, Isconova and Vertex Ltd.
Charlotte Sofie Bergsagel Berg-Svendsen
Board member
About Close
Charlotte Berg-Svendsen has broad professional experience across the life science industry from start-ups and Big Corporates within the biotech, medtech and pharmaceutical sectors. She has held leading international roles and board positions in life science companies such as Pronova Biopharma ASA, BASF SE Vitux AS and Kappa Biosciences AS, including Chief Legal Officer and VP of Strategic Innovation and IP Management at Pronova and BASF, and Chief Commercial Officer in PreDiagnostics AS. She is currently CEO of Cruda AS and chair of the board in Mo Industripark AS. Charlotte Berg-Svendsen holds a Master of Law (LLM) from the University of Oslo and an MBA from the Norwegian School of Economics (NHH).
Martin Welschof
Board member
About Martin Close
Mr. Welschof brings over three decades of international biotech leadership, combining deep scientific expertise with a track record of building, partnering and financing clinical-stage companies in public markets.
He is currently CEO of BioInvent International AB (Nasdaq Stockholm), a clinical-stage immuno-oncology company. He has previously served as CEO of Affitech A/S (Nasdaq Copenhagen) and CEO of Opsona Therapeutics (Dublin), and as Director of Technology at Axaron Bioscience AG (Heidelberg), giving him hands-on experience of leading listed life science companies through clinical development, partnering and capital raising.
Martin holds a PhD (Dr. rer. nat.) in recombinant antibody technology and completed postdoctoral training at the German Cancer Research Center (DKFZ), Department of Recombinant Antibody Technology, and at the University of Heidelberg, Department of Transplantation Immunology.